MIRA Pharmaceuticals Announces New Preclinical Data On Mira-55 Cannabinoid Analog In Development For Chronic Inflammatory Pain Showing Favorable Anxiety-Reducing Effect While Delivering Pain Relief

Loading news article.

MIRA Pharmaceuticals Announces New Preclinical Data On Mira-55 Cannabinoid Analog In Development For Chronic Inflammatory Pain Showing Favorable Anxiety-Reducing Effect While Delivering Pain Relief | WAPE

MIRA Pharmaceuticals Announces New Preclinical Data On Mira-55 Cannabinoid Analog In Development For Chronic Inflammatory Pain Showing Favorable Anxiety-Reducing Effect While Delivering Pain Relief

Article summary

Related companies

Comments —